Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.42 |
| ▸ | MPL | P40238 | 5/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102494 | 0.92 | RARB (0.46) | RARBMPLRARARARGHSD11B1 | |
| SCHEMBL20102499 | 0.86 | RARB (0.38) | RARBTLR8RARARARGGCGR | |
| SCHEMBL20102500 | 0.85 | CTSL (0.40) | RARBTLR8GCGRGPR3TSHR | |
| SCHEMBL16229872 | 0.84 | RARB (0.46) | RARBMPLRARARARGHSD11B1 | |
| SCHEMBL9493798 | 0.83 | RARB (0.45) | RARBMPLRARARARGHSD11B1 | |
| SCHEMBL9485527 | 0.83 | RARB (0.45) | RARBMPLRARARARGHSD11B1 | |
| SCHEMBL20117903 | 0.82 | MPL (0.36) | RARBMPLHSD17B10 | |
| SCHEMBL9486110 | 0.81 | RARB (0.47) | RARBRARARARGHSD11B1TSHR | |
| SCHEMBL2208150 | 0.81 | RARB (0.47) | RARBMPLRARARARGHSD11B1 | |
| SCHEMBL12740085 | 0.81 | RARB (0.44) | RARBMPLRARARARGHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | RARB 1858/4885MPL 4474/4885TLR8 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.